Issue Date: January 30, 2012
Amgen And Celgene Acquire Cancer Drug Companies
Amgen will pay $1.2 billion for Micromet, which brings bispecific T-cell engager (BiTE) antibody technology. BiTE antibodies bind to both tumor cells and T cells, causing cancer cell death and proliferation of more T cells at the tumor site. Amgen also gets blinatumomab, a BiTE antibody in Phase . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society